newsfilter
← Latest News
GlobeNewswire·

Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026

  • Scribe Therapeutics will present at the American Heart Association's Scientific Sessions in Chicago from November 6-9, 2026.
  • A late-breaking presentation will report that STX-1150 provides persistent LDL cholesterol control for at least two years after a single dose in non-human primates.
  • STX-1150 is an epigenetic silencing therapy designed to repress PCSK9 without permanently altering DNA and is currently in a Phase 1 trial for elevated LDL-C.
  • A second presentation will reveal that STX-1200 achieves robust & durable reduction of lipoprotein(a) across preclinical models via CRISPR-based gene editing of the LPA gene.
  • CEO Benjamin Oakes, Ph.D., will participate in two AHA Innovation Forum sessions on November 6, 2026, covering entrepreneurship & AI in cardiovascular innovation.
  • Co-founder Elena Smekalova, Ph.D., will present the preclinical data for STX-1200 on November 7, 2026.